Skip to main content
. 2021 Feb 23;56(4):303–322. doi: 10.1007/s00535-021-01769-0

Fig. 6.

Fig. 6

Forest plots of peptic ulcer risk between COX-2 selective inhibitor and NSAID therapy in the randomized control trials (a gastric ulcer, b duodenal ulcer). In meta-analysis, the incidence of gastric (risk ratio 0.21; 95% CI 0.18–0.25) (a) and duodenal ulcers (risk ratio 0.38; 95% CI 0.29–0.51) (b) are lower in patients using COX-2 selective inhibitors than in patients using NSAIDs